Subscribe or Manage Preferences

VBCR - December 2016, Vol 5, No 6

Patients with inflammatory diseases are at increased risk for perioperative infection, which has been associated with significant morbidity and mortality.
Value-based pricing is a practical cost-saving method for challenging the current basis used to determine how much patients pay for prescription medications, according to a new policy adopted by the American Medical Association.
Tocilizumab treatment weekly or every other week for 52 weeks with a 26-week prednisone taper was superior to a short and long course of tapered prednisone treatment in patients with giant cell arteritis (GCA).
The European League Against Rheumatism (EULAR) and the Pediatric Rheumatology European Society (PReS) have jointly developed the first European guidelines for the transition of younger patients from pediatric to adult rheumatic care.
  • Application and Population Management System Undergoing Testing for the Management of Flares in Patients with Rheumatoid Arthritis
  • Humana Adds MDLIVE Telemedicine Technology Benefit to Select Medicare Advantage Plans
  • Applications Being Developed to Provide Patients with Timely Drug Cost Information
  • Pregnancy Outcomes in Ankylosing Spondylitis
  • Prescribing Patterns for JIA in the United Kingdom
  • Sifalimumab Is a Potential New Treatment Approach for Patients with Systemic Lupus Erythematosus
Washington, DC—Rheumatology practices in the United States vary widely in their performance in meeting key quality measures for patient care, and these variations may affect physician reimbursement under the new Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) laws, the results of a study presented at the 2016 Annual Meeting of the American College of Rheumatology (ACR) suggest.
Washington, DC—What does the future of rheumatology specialists look like in the United States? By 2030, there will be an approximately 140% projected increase in demand coupled with a 31% decrease in adult rheumatologists, according to the American College of Rheumatology (ACR)’s 2015 Workforce Study. The last ACR Workforce Study was conducted in 2005.
Washington, DC—Long-term follow-up of the MAINRITSAN trial confirmed primary results of the trial showing the superiority of rituximab compared with azathioprine as maintenance therapy for antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. At 60 months, the rate of overall survival was 100% for rituximab versus 93% for azathioprine (P = .045). The rate of relapse-free survival was 57.9% versus 37.2%, respectively (P = .012).
  • Maci Approved for the Reparation of Cartilage Defects
Page 1 of 2
Results 1 - 10 of 15
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology